NO2625199T3 - - Google Patents

Info

Publication number
NO2625199T3
NO2625199T3 NO11764764A NO11764764A NO2625199T3 NO 2625199 T3 NO2625199 T3 NO 2625199T3 NO 11764764 A NO11764764 A NO 11764764A NO 11764764 A NO11764764 A NO 11764764A NO 2625199 T3 NO2625199 T3 NO 2625199T3
Authority
NO
Norway
Application number
NO11764764A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44759699&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2625199(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of NO2625199T3 publication Critical patent/NO2625199T3/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO11764764A 2010-10-08 2011-10-07 NO2625199T3 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39138810P 2010-10-08 2010-10-08
PCT/EP2011/067522 WO2012045848A1 (fr) 2010-10-08 2011-10-07 Méthodes de traitement du psoriasis au moyen d'antagonistes de il-17

Publications (1)

Publication Number Publication Date
NO2625199T3 true NO2625199T3 (fr) 2018-04-21

Family

ID=44759699

Family Applications (1)

Application Number Title Priority Date Filing Date
NO11764764A NO2625199T3 (fr) 2010-10-08 2011-10-07

Country Status (27)

Country Link
US (6) US9717791B2 (fr)
EP (4) EP3792281A1 (fr)
JP (2) JP5537740B2 (fr)
KR (3) KR20130110179A (fr)
CN (2) CN103154031A (fr)
AU (1) AU2011311482B2 (fr)
BR (1) BR112013008501A2 (fr)
CA (1) CA2813900C (fr)
CL (1) CL2013000930A1 (fr)
CY (1) CY1119942T1 (fr)
DK (1) DK2625199T3 (fr)
ES (1) ES2660770T3 (fr)
HK (1) HK1247932A1 (fr)
HR (1) HRP20180301T1 (fr)
HU (1) HUE038334T2 (fr)
IL (1) IL225310A (fr)
LT (1) LT2625199T (fr)
MA (1) MA34646B1 (fr)
MX (1) MX356279B (fr)
NO (1) NO2625199T3 (fr)
PL (1) PL2625199T3 (fr)
PT (1) PT2625199T (fr)
RU (2) RU2665954C1 (fr)
SG (1) SG188979A1 (fr)
SI (1) SI2625199T1 (fr)
TW (2) TWI564022B (fr)
WO (1) WO2012045848A1 (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
CN102821787B (zh) 2010-01-15 2015-07-29 麒麟-安姆根有限公司 抗体制剂和治疗方案
CN102906118B (zh) 2010-05-20 2017-07-28 埃博灵克斯股份有限公司 与her3相关的生物材料
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
EP2783014A1 (fr) * 2011-11-21 2014-10-01 Novartis AG Procédés de traitement du rhumatisme psoriasique (psa) utilisant des antagonistes d'il-17 et des allèles répondeurs ou non répondeurs à psa
CA2906382A1 (fr) * 2013-03-15 2014-09-25 Amgen Inc. Methodes de traitement du psoriasis a l'aide d'un anticorps anti-il-23
CN105307675A (zh) * 2013-03-15 2016-02-03 美国安进公司 使用抗il23抗体治疗克罗恩氏病的方法
EP3033107A1 (fr) 2013-08-15 2016-06-22 Novartis AG Méthodes de traitement du psoriasis pustuleux généralisé (gpp) au moyen d'antagonistes d'il-17
CA2935046C (fr) * 2013-12-27 2021-04-13 Osaka University Vaccin ciblant l'il-17a
RU2577228C2 (ru) * 2014-03-14 2016-03-10 Закрытое Акционерное Общество "Биокад" Анти-il-17-антитела, способ их получения и способ применения
KR20160130248A (ko) * 2014-03-31 2016-11-10 키린-암젠, 인코포레이티드 손발톱 및 두피 건선의 치료 방법
US11548940B2 (en) * 2014-05-15 2023-01-10 Rani Therapeutics, Llc Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
AU2015258859B2 (en) 2014-05-15 2020-07-23 Rani Therapeutics, Llc Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins
US20170298136A1 (en) * 2014-08-26 2017-10-19 Kirin-Amgen, Inc. Method for treating psoriasis patient which received anti-tnf-alpha antibody therapy
KR20170045240A (ko) * 2014-09-10 2017-04-26 노파르티스 아게 건선성 관절염 환자에서 구조적 손상의 진행을 억제하기 위한 il-17 길항제의 용도
AR103173A1 (es) * 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
AR103172A1 (es) * 2014-12-22 2017-04-19 Novartis Ag Reducción selectiva de residuos de cisteina en anticuerpos il-17
US10500273B2 (en) 2015-03-02 2019-12-10 180 Therapeutics Lp Method of treating a localized fibrotic disorder using an IL-33 antagonist
EP3167892A1 (fr) 2015-11-10 2017-05-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés et compositions pharmaceutiques pour la prévention ou le traitement de maladies intestinales inflammatoires
US11492396B2 (en) * 2015-10-27 2022-11-08 UCB Biopharma SRL Methods of treatment using anti-IL-17A/F antibodies
EP3487881A1 (fr) * 2016-07-19 2019-05-29 Novartis AG Procédés de traitement du psoriasis de type en plaques d'apparition récente au moyen d'antagonistes de l'il-17
WO2018096467A1 (fr) * 2016-11-28 2018-05-31 Novartis Ag Méthodes de traitement de l'acné à l'aide d'antagonistes de l'interleukine-17 (il -17)
WO2018158741A1 (fr) * 2017-03-03 2018-09-07 Novartis Ag Modification de la maladie du psoriasis suite à un traitement à long terme avec un antagoniste de l'il-17
CA3073597A1 (fr) * 2017-08-23 2019-02-28 Eli Lilly And Company Traitement du psoriasis genital
TWI725532B (zh) * 2018-09-11 2021-04-21 美商美國禮來大藥廠 治療牛皮癬之方法
US20220267432A1 (en) 2019-07-30 2022-08-25 Jiangsu Hengrui Medicine Co., Ltd. Method for treating autoimmune disease by il-17 antagonist
WO2022184114A1 (fr) * 2021-03-03 2022-09-09 苏州盛迪亚生物医药有限公司 Procédé de traitement de maladies auto-immunes et d'inflammations avec un anticorps anti-il-17
WO2023186174A1 (fr) * 2022-04-01 2023-10-05 Zai Lab (Shanghai) Co., Ltd. Formulation topique comprenant une molécule de liaison à l'il-17 et ses utilisations
CN116593718B (zh) * 2023-07-18 2023-09-15 军科正源（北京）药物研究有限责任公司 用于检测司库奇尤单抗抗药性抗体的试剂

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9422306D0 (en) * 1994-11-04 1994-12-21 Sandoz Ltd Organic compounds
US6093745A (en) * 1997-11-25 2000-07-25 Psorx, L.L.C. Methods and composition for treating skin proliferative diseases
AU2002224417A1 (en) * 2000-10-18 2002-04-29 Immunex Corporation Methods for treating il-18 mediated disorders
US20090280065A1 (en) * 2006-04-10 2009-11-12 Willian Mary K Uses and Compositions for Treatment of Psoriasis
TWI556829B (zh) * 2004-04-09 2016-11-11 艾伯維生物技術有限責任公司 用於治療ＴＮＦα相關失調症之多重可變劑量療法
GB0417487D0 (en) * 2004-08-05 2004-09-08 Novartis Ag Organic compound
CA2621086A1 (fr) * 2005-09-01 2007-03-08 Schering Corporation Utilisation d'antagonistes de l'il-23 et de l'il-17 pour le traitement de la maladie inflammatoire oculaire auto-immune
PL2481753T3 (pl) * 2005-12-13 2018-09-28 Eli Lilly And Company Przeciwciała anty-IL-17
TW200815469A (en) * 2006-06-23 2008-04-01 Astrazeneca Ab Compounds
RU2367429C2 (ru) 2007-01-30 2009-09-20 Государственное учреждение Научно-исследовательский институт клинической иммунологии СО РАМН Способ лечения псориаза
WO2008150490A2 (fr) * 2007-06-01 2008-12-11 Abbott Biotechnology Ltd. Compositions et utilisations pour le traitement du psoriasis et de la maladie de crohn
RU2341272C1 (ru) 2007-10-22 2008-12-20 Левон Никитович Мкртчян Средство для неспецифической иммунотерапии
MY153893A (en) * 2008-09-29 2015-04-15 Roche Glycart Ag Antibodies against human il17 and uses thereof

Also Published As

Publication number Publication date
WO2012045848A1 (fr) 2012-04-12
HRP20180301T1 (hr) 2018-03-23
CL2013000930A1 (es) 2014-03-28
RU2591083C2 (ru) 2016-07-10
JP5537740B2 (ja) 2014-07-02
TWI548419B (zh) 2016-09-11
KR20150018595A (ko) 2015-02-23
US20210113688A1 (en) 2021-04-22
AU2011311482A1 (en) 2013-04-04
KR20130110179A (ko) 2013-10-08
KR101620771B1 (ko) 2016-05-12
CA2813900A1 (fr) 2012-04-12
KR20140097566A (ko) 2014-08-06
AU2011311482B2 (en) 2014-05-29
CA2813900C (fr) 2017-01-10
TWI564022B (zh) 2017-01-01
US20210162044A1 (en) 2021-06-03
BR112013008501A2 (pt) 2016-08-16
IL225310A0 (en) 2013-06-27
HUE038334T2 (hu) 2018-10-29
US20170304439A1 (en) 2017-10-26
EP3299390A1 (fr) 2018-03-28
CN103154031A (zh) 2013-06-12
SI2625199T1 (en) 2018-03-30
CN107029234A (zh) 2017-08-11
MX356279B (es) 2018-05-22
HK1247932A1 (zh) 2018-10-05
JP2014114288A (ja) 2014-06-26
CY1119942T1 (el) 2018-12-12
US20200171147A1 (en) 2020-06-04
US20230321231A1 (en) 2023-10-12
RU2013120957A (ru) 2014-11-20
TW201216984A (en) 2012-05-01
US10583190B2 (en) 2020-03-10
US20130202610A1 (en) 2013-08-08
EP3792281A1 (fr) 2021-03-17
PT2625199T (pt) 2018-02-28
ES2660770T3 (es) 2018-03-26
EP4137514A1 (fr) 2023-02-22
EP2625199A1 (fr) 2013-08-14
MX2013003916A (es) 2013-06-03
PL2625199T3 (pl) 2018-04-30
RU2665954C1 (ru) 2018-09-05
US11534490B2 (en) 2022-12-27
LT2625199T (lt) 2018-03-12
IL225310A (en) 2016-10-31
TW201630625A (zh) 2016-09-01
MA34646B1 (fr) 2013-11-02
SG188979A1 (en) 2013-05-31
US9717791B2 (en) 2017-08-01
DK2625199T3 (en) 2018-02-26
EP2625199B1 (fr) 2017-11-22
JP2013543501A (ja) 2013-12-05

Similar Documents

Publication Publication Date Title
BR112013013385A2 (fr)
BR112013008959A2 (fr)
BR112012031500A2 (fr)
BR112012029986A2 (fr)
BR112012019354A2 (fr)
BR112012002126A2 (fr)
BR112012017960A2 (fr)
BR112013006400A2 (fr)
NO2625199T3 (fr)
BR112012031826A2 (fr)
BR112012023249A2 (fr)
BR112012016456A2 (fr)
BR112012018256A2 (fr)
BR112013010949A2 (fr)
BR112013003284A2 (fr)
BR112013002646A2 (fr)
BR112012022788A2 (fr)
BR112013012726A2 (fr)
BR112012023446A2 (fr)
BR112013006825A2 (fr)
BR112012016895A2 (fr)
BR112013007728A2 (fr)
BR112012030078A2 (fr)
BR112013015388A2 (fr)
BR112013007731A2 (fr)